- Home
- GCTS vs OTLK Comparison
GCTS vs OTLK Comparison
Compare GCTS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCTS | OTLK |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | 126 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.4M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GCTS | OTLK |
|---|---|---|
| Price | $2.47 | $1.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $3.50 | $2.50 |
| AVG Volume (30 Days) | 3.3M | ★ 15.4M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $1,052.30 | $1,430.98 |
| Revenue Next Year | $140.29 | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.16 |
| 52 Week High | $3.93 | $3.39 |
Technical Indicators
Market Signals| Indicator | GCTS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 67.18 |
| Support Level | $2.35 | $1.60 |
| Resistance Level | $3.21 | $1.98 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 17.96 | 65.53 |
Price Performance
Historical ComparisonAbout GCTS GCT Semiconductor Holding Inc.
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.